Results 211 to 220 of about 56,774 (264)

Combined biologic therapy targeting B cells and eosinophils in relapsing multiple sclerosis and severe asthma: a case report of ofatumumab and mepolizumab. [PDF]

Front Immunol
Zanghì A, Di Filippo PS, Rutigliano C, Avolio C, D'Amico E.   +4 more
europepmc   +1 more source

Differences in the Neural Substrate for Physical and Mental Quality of Life in Patients With Multiple Sclerosis. [PDF]

Brain Behav
Fujimori J, Nei M, Umezawa S, Misu T, Nakashima I.   +4 more
europepmc   +1 more source

Rewriting the prognosis of multiple sclerosis in Brazil: a 25-year perspective on evolving diagnostic criteria. [PDF]

Arq Neuropsiquiatr
Callegaro D, Silva GD.
europepmc   +1 more source

Multiple Sclerosis With Migraine and Pyoderma Gangrenosum Treated With Ofatumumab and Erenumab. [PDF]

Cureus
Motegi H, Komatsu T, Onda A, Sakai K, Iguchi Y.   +4 more
europepmc   +1 more source

Inflammatory bowel disease therapies and demyelinating diseases: a practical guide to therapeutic benefit and risk. [PDF]

J Crohns Colitis
Honap S, Debouverie M, Filippi M, Selchen D, Jairath V, Danese S, Peyrin-Biroulet L.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Relapsing-remitting tumefactive multiple sclerosis

Multiple Sclerosis Journal, 2005
Tumefactive multiple sclerosis (MS) is a rare form of demyelinating disease. The natural course of the disease has been characterized as presenting with a mass-like demyelinating lesion converting to typical relapsing-remitting disease with future exacerbations.
Stephen M, Selkirk, Jiong, Shi
openaire   +2 more sources